What are the names of the BTK inhibitors?
What are the names of the approved drugs that inhibit Bruton's tyrosine kinase? What are they used to treat?
The Bruton's tyrosine kinase (BTK) inhibitors include Imbruvica (ibrutinib), Calquence (acalabrutinib), Brukinsa (zanubrutinib), and Jaypirca (pirtobrutinib).
Imbruvica (ibrutinib) Capsules, Tablets, and Oral Suspension
FDA Approved: November 13, 2013
Company: Janssen Biotech, Inc.
Treatment for adult patients with:
- Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
- Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion.
- Waldenström’s Macroglobulinemia (WM).
Treatment of adult and pediatric patients age 1 year and older with:
- Chronic Graft Versus Host Disease (cGVHD) after failure of one or more lines of systemic therapy.
Calquence (acalabrutinib) Capsules and Tablets
FDA Approved: October 31, 2017
Company: AstraZeneca
Treatment for adult patients with:
- Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Brukinsa (zanubrutinib) Capsules
FDA Approved: November 14, 2019
Company: BeiGene, Ltd.
Treatment for adult patients with:
- Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Waldenström’s Macroglobulinemia (WM).
- Marginal Zone Lymphoma (MZL) who have received at least one anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall
response rate. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory trial. - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Follicular Lymphoma (FL) (relapsed or refractory) in combination with obinutuzumab, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response
rate and durability of response. Continued approval for this indication may
be contingent upon verification and description of clinical benefit in a
confirmatory trial.
Jaypirca (pirtobrutinib) Tablets
FDA Approved: January 27, 2023
Company: Eli Lilly and Company
Treatment for adult patients with:
- Mantle Cell Lymphoma (MCL) who have received at least two prior therapies, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Related questions
Read next
Acalabrutinib vs. ibrutinib: How do they compare?
A 2021 phase III study in the Journal of Clinical Oncology found that while both medications have similar efficacy, acalabrutinib was better tolerated with fewer side effects. Continue reading
How quickly does Imbruvica (ibrutinib) work?
In some people, very good partial clinical responses to Imbruvica may occur within three to six months. Imbruvica is usually given until disease progression or unacceptable toxicity occurs, or in the case of graft vs host disease, recurrence of an underlying malignancy. The average duration of Imbruvica therapy in clinical trials has been around 41 months (range, 2–51 months). Continue reading
Does ibrutinib cause hair loss?
Hair loss (alopecia) has not been noted as a side effect of ibrutinib (Imbuvica) in the product label. Textural hair changes (softening, straightening or curliness) and nail changes (brittle fingernails and toenails) were noted in a study evaluating ibrutinib use over the long term for treatment of chronic lymphocytic leukemia (CLL). Continue reading
Related medical questions
- Is Imbruvica a chemotherapy drug?
- Who makes Imbruvica?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- How does the drug Rituxan work?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- Is Venclexta (venetoclax) chemotherapy?
- Does Truxima make you gain weight?
- How do you prepare for a Rituxan infusion?
- What causes infusion reactions to rituximab?
- How effective is Venclexta?
- How long do you take Venclexta for?
- Is Truxima a chemotherapy drug?
- How is Arzerra administered and how long to work?
- Is Zydelig a chemotherapy drug?
- How is Bendeka different to Treanda?
- What is Zydelig used for and how does it work?
- What is Arzerra used for and how does it work?
- How long does it take for Jaypirca to work?
- What is the difference between Rituxan and Rituxan Hycela?
- Who makes Leukeran, and where is it made?
- How is Rituxan Hycela administered?
- What is the success rate of Breyanzi?
- How does Venclexta work?
- What type of drug is Copiktra?
Drug information
Related support groups
- Ibrutinib (10 questions, 14 members)
- Imbruvica (8 questions, 37 members)
- Calquence (1 questions, 3 members)
- Zanubrutinib (1 questions, 3 members)
- Brukinsa (1 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (26 questions, 57 members)
- Follicular Lymphoma (15 questions, 15 members)
- Mantle Cell Lymphoma (9 questions, 9 members)